Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study.
Alzheimers Dement
; 20(3): 2072-2079, 2024 03.
Article
en En
| MEDLINE
| ID: mdl-38215191
ABSTRACT
INTRODUCTION:
Identification of Alzheimer's disease (AD) needs inexpensive, noninvasive biomarkers, with validation in all populations.METHODS:
We collected plasma markers in older American Indian individuals phosphorylated-tau181 (pTau181); amyloid-beta (Aß) 40,42; glial fibrillary acidic protein (GFAP); and neurofilament light chain (NfL). Plasma markers were analyzed for discriminant properties with cognitive status and etiology using receiver operating characteristic (ROC) analysis.RESULTS:
PTau181, GFAP, NfL plasma values were significantly associated with cognition, but Aß were not. Discriminant performance was moderate for individual markers, with pTau181, GFAP, NfL performing best, but an empirically selected panel of markers (age, sex, education, pTau181, GFAP, NfL, Aß4240 ratio) had excellent discriminant performance (AUC > 0.8).DISCUSSION:
In American Indian individuals, pTau181 and Aß values suggested more common pathology than in majority populations. Aß was less informative than in other populations; however, all four markers were needed for a best-performing dementia diagnostic model. These data validate utility of AD plasma markers, while suggesting population-specific diagnostic characteristics.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Indio Americano o Nativo de Alaska
/
Enfermedad de Alzheimer
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Humans
Idioma:
En
Revista:
Alzheimers Dement
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos